Evogene Ltd.
EVGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $10 | $9 | $8 | $13 |
| - Cash | $6 | $8 | $7 | $15 |
| + Debt | $3 | $13 | $13 | $13 |
| Enterprise Value | $7 | $14 | $14 | $10 |
| Revenue | $0 | $1 | $2 | $2 |
| % Growth | -64.7% | -63.8% | 51.7% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -40.4% | 51.8% | 10.3% | 16.3% |
| EBITDA | -$2 | -$3 | -$2 | $1 |
| % Margin | -634% | -288% | -79.5% | 46.7% |
| Net Income | $4 | -$4 | -$3 | $0 |
| % Margin | 1,241.7% | -504.8% | -105.9% | 26.5% |
| EPS Diluted | 0.44 | -0.62 | -0.38 | 0.063 |
| % Growth | 171% | -63.2% | -705.1% | – |
| Operating Cash Flow | -$4 | -$2 | -$5 | -$5 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$4 | -$2 | -$5 | -$6 |